Bionano Genomics, Inc.
Every calculator, already run for BNGO
Open the full toolkit →You have the numbers on BNGO. Get the argument.
A written report on which of these readings actually decide the outcome for Bionano Genomics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering BNGOAnalyst Price Target Disagreement for Bionano Genomics, Inc.
Wall Street's bull case implies +305% from the current price; the bear case implies +170%. A 135% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BNGO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bionano Genomics, Inc.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molec…
BNGO — frequently asked
Is BNGO a buy right now?
Wall Street's consensus rating on Bionano Genomics, Inc. is none across 1 analysts, with a mean price target of $5.00 (+238% vs. the current $1.48). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BNGO overvalued?
BNGO trades at — trailing earnings, against a DCF fair value of $3 per share. The current price implies -6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BNGO's next earnings date?
Bionano Genomics, Inc. is next scheduled to report earnings around Nov 12, 2026. A full BNGO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Bionano Genomics, Inc.?
Analysts covering Bionano Genomics, Inc. (BNGO) range from a bear-case target of $4.00 to a bull-case high of $6.00, with a mean consensus target of $5.00 across 2 analysts. The spread of $2.00 (135% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bionano Genomics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bionano Genomics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BNGO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bionano Genomics, Inc., in minutes. 3 free reports included with every account — no credit card required.